Indeed, in the phase II trial of everolimus in a pan-cancer cohort of patients with inactivating TSC1/2 or activating mTOR mutations, the response rate and DCB rate was numerically lower than that for cohort B2D in the current report29. This evidence concerns the gene TSC1 and cancer.